We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Diurnal Group plc (DNL) Ordinary 5p

Sell:57.00p Buy:59.00p 0 Change: 0.50p (0.85%)
Market closed |  Prices as at close on 29 November 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:57.00p
Buy:59.00p
Change: 0.50p (0.85%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 29 November 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:57.00p
Buy:59.00p
Change: 0.50p (0.85%)
Market closed |  Prices as at close on 29 November 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • Diurnal agrees special protocol with FDA for Chronocort study

    12 July 2021 10:10

    (Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or...

  • Diurnal gets UK approval for 'Efmody' treatment

    2 July 2021 10:02

    (Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for...

  • Diurnal granted European patent for Alkindi

    23 April 2021 10:31

    (Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by...

  • Alkindi sales drive revenue higher for Diurnal

    23 February 2021 16:23

    (Sharecast News) - Speciality pharmaceuticals company Diurnal reported 6% growth in first-half total revenue in its interim results on Tuesday, to £1.21m.

  • Diurnal enters Alkindi agreement for China region

    27 January 2021 11:09

    (Sharecast News) - Specialty pharmaceutical company Diurnal Group has entered into an exclusive licence agreement for its product 'Alkindi', or hydrocortisone granules in capsules for opening, with...

  • Diurnal gets European patent for 'Alkindi'

    20 November 2020 12:04

    (Sharecast News) - Speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office...

  • Diurnal up as its partner advances Swiss authorisation for 'Alkindi'

    21 October 2020 15:40

    (Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced on Wednesday that its marketing and distribution partner in Switzerland, EffRx Pharmaceuticals, has submitted a market...

  • Diurnal raising up to £10m in placing and open offer

    9 October 2020 16:13

    (Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced a proposed conditional placing with institutional investors to raise up to £8m before expenses on Friday, at a price of 60p per...

  • Diurnal signs two new distribution agreements in Europe

    3 September 2020 11:35

    (Sharecast News) - Speciality pharmaceutical company Diurnal Group announced two further European market and distribution agreements for its products 'Alkindi', or hydrocortisone granules in...

  • Diurnal raises at least ?7m through conditional placing

    6 March 2020 10:07

    (Sharecast News) - Speciality pharmaceutical company Diurnal Group announced a conditional placing with institutional investors on Friday, to raise at least ?7m before expenses, at a price of 32p per new share.

  • Diurnal clears FDA hurdle for 'Alkindi Sprinkle'

    13 February 2020 09:47

    (Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Thursday that its new drug application (NDA) for 'Alkindi', or hydrocortisone granules in capsules for opening and to...

  • Diurnal narrows loss as it progresses drugs to market

    11 February 2020 13:45

    (Sharecast News) - Speciality pharmaceutical company Diurnal Group narrowed its first-half loss by 53% to ?4.6m, it announced on Tuesday, which it said reflected improved revenues and a reduction in clinical...

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2021. All rights reserved.

Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.